Clinical Trial Update: Ivosidenib and Ruxolitinib in Patients With Advanced Myeloproliferative Neoplasms (MPNs) That Have an IDH1 Gene Mutation [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial is evaluating the combination of ivosidenib and ruxolitinib in adults with advanced myeloproliferative neoplasms harboring IDH1 mutatio…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Myeloproliferative Neoplasms

Drugs mentioned

• Ivosidenib (ivosidenib)
• Ruxolitinib (ruxolitinib)

Snippet

Sponsor: University of Chicago | Conditions: Myeloproliferative Neoplasms | Phase 1 | Status: RECRUITING